Please assess the completion status of the following clinical trial:

Trial Title: Phase III Study of Tolvaptan Tablet to Treat Cirrhosis Ascites

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion criteria:~1. Patients diagnosed with liver cirrhosis clinically or pathologically;~2. Patients with ascites confirmed by Type-B ultrasound scan after receiving combination therapies of oral loop diuretics and aldosterone antagonists for at least 4 days with the fixed usage and dosage~3. Inpatients or patients who can be hospitalized for this study from Day -3 (Screening) to Day 8 (the day for efficacy evaluation);~4. Patients with body weight change within ±1.0 kg in the 2 days prior to initiation of treatment (Day -2 and Day -1)~5. Age: 18 to 75 years, inclusive(at the time informed consent is obtained);~6. Genders: men or women;~7. Patients who have signed informed consent form.~Exclusion criteria:~1. Patients with any of the following diseases, complications or symptoms:~   * Hepatic encephalopathy (hepatic coma of grade II or higher1）);~  * Malignant ascites (patients have tumor cells detected in ascites if malignant ascites be highly suspected);~  * Uncontrolled spontaneous bacterial peritonitis;~  * Patients who are likely to experience alimentary tract hemorrhage during the study;~  * Heart failure (NYHA2） grade III or IV);~  * Anuresis (daily urine volume is less than 100mL);~  * Dysuria due to urinary tract stricture, urinary calculus, tumor in the urinary tract or other cause.~2. Patients with history of :~   * Alimentary tract hemorrhage within 10 days prior to screening;~  * Cerebral accident suffered within 30 days prior to screening;~  * Past history of hypersensitivity or idiosyncratic reaction to benzazepine derivatives (Benazepril).~3. Patients with systolic pressure below 90mmHg at screening;~4. Patients with any of the following abnormal laboratory parameters at screening:~   * Serum creatinine \>1.5x upper limit of normal range;~  * Serum Na+\>145mmol/L (or higher than upper limit of normal range);~  * Serum K+\>5.5mmol/L;~5. Patients with Child-pugh score3）\>12;~6. Patients who are unable to take medicine orally;~7. Female patients who are pregnant, lactating, or who are at child-bearing age without using acceptable contraceptive means;~8. Patients who received blood products including albumin within 4 days prior to the initiation of treatment~9. Patients who participated in any clinical trial other than tolvaptan within one month prior to screening;~10. Patients who participated in Tolvaptan trials and took Tolvaptan previously;~11. Patients otherwise judged by the investigator, to be inappropriate for inclusion in the study.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Tolvaptan 15mg (Type: EXPERIMENTAL): Tablet;15mg/tab
- Tolvaptan 7.5mg (Type: EXPERIMENTAL): Tablet;7.5mg/tab
- Placebo (Type: PLACEBO_COMPARATOR): Tolvaptan 0mg/tab

Based on this trial design, predict the completion outcome and termination type (if applicable).